Because cAMP exerts opposite effects on cell proliferation in different cell types, we undertook to study its effect on the mitogen-activated protein kinase (MAPK) pathway in three cell lines (Rat-i, Swiss-3T3, and COS-7) chosen for their different mitogenic responses to cAMP. We measured the effect of cAMP on MAPK, MEK, and Raf-1 activities after stimulation by agonists acting through a tyrosine kinase receptor (epidermal growth factor) or a G protein-coupled receptor (lysophosphatidic acid). In Rat-i cells we found that cAMP strongly inhibited all three activities (MAPK, MEK, and Raf-1), in good agreement with its effect on cell proliferation in these cells. In Swiss-3T3 and COS-7 cells, on the contrary, cAMP did not inhibit epidermal growth factor-and lysophosphatidic acid-induced stimulation of MAPK and MEK activities, and even stimulated MAPK activity slightly on its own. Again these results are in good agreement with the proliferative effect of cAMP in Swiss-3T3 cells. Raf-1 activity, on the other hand, was inhibited by cAMP in Swiss-3T3 and COS-7 as it was in Rat-i cells. This result indicates that signaling pathways in Swiss-3T3 and COS-7 cells can activate MEK and MAPK in a Raf-l-independent and cAMP-insensitive manner. Our results add to growing evidence for the existence of Ras-and/or Raf-l-independent pathways leading to MEK and MAPK activation.
INTRODUCTION
Mitogen-activated protein kinases (MAPKs),1 also known as extracellular signal-regulated kinases (ERKs), are a family of protein-serine/threonine kinases that become activated in response to growth factors, hormones, neurotransmitters, and other extracellular stimuli. These kinases exert mitogenic effects by phosphorylating a broad array of substrates (for review, see Marshall, 1994 ). *Present address: Sugen Inc., 515 Galveston Drive, Redwood City, CA 94063. MAPKs are regulated by a kinase-mediated signaling cascade. A MAPK kinase (MAPKK) (Seger et al., 1992) , also known as MEK (Crews et al., 1992) , activates MAPKs by catalyzing MAPK phosphorylation on both threonine and tyrosine residues (Anderson et al., 1990) . MEK itself is activated by phosphorylation on serine residues by a MAPK kinase kinase (MKKK) (Alessi et al., 1994; Zheng and Guan, 1994) . Each phosphorylation in the cascade can be performed by two or more proteins, including two closely related MAPKs, p44mapk (ERK1) and p42maPk (ERK2) (Boulton et al., 1991) , two isoforms of MEK (MEK1 and MEK2) (Zheng and Guan, 1993a) , and, at the MKKK level, three Raf kinase isoforms (Raf-1, Raf-A, and Raf-B) (Huleihel et al., 1986; Sithanandam et al., 1990; Stephens et al., 1992) and a protein called MEKK (LangeCarter et al., 1993) . This cascade of three consecutive protein kinases is highly conserved throughout eukaryotic evolution (reviewed in Neiman, 1993) , and similar kinase cascades transduce nonmitogenic signals such as stress or osmotic shock (Galcheva-Gargova et al., 1994; Han et al., 1994) .
MAPKs can be activated by extracellular stimuli that act via tyrosine kinase receptors or G protein-coupled receptors. Activated receptor tyrosine kinases, such as the EGF and PDGF receptors, trigger activation of p2lras by a well-established pathway involving the Grb2/SEM5 and SOS proteins (reviewed in McCormick, 1994) . Activated p2lras binds Raf-1 (Moodie et al., 1993; van Aelst et al., 1993; Vojtek et al., 1993) and recruits it to the plasma membrane (Leevers et al., 1994; Stokoe et al., 1994) , where it is activated to phosphorylate MEK. Less is known about how G proteincoupled receptors stimulate the MAPK pathway. We and others (Crespo et al., 1994; Faure et al., 1994) have shown that G protein fry subunits are involved in this response, and clear evidence implicates Ras and Raf as mediators of the MAPK response to these receptors in some cases Howe and Marshall, 1993; van Corven et al., 1993; Winitz et al., 1993) . In addition, poorly characterized pathways independent of Ras and Raf can lead to MAPK activation in response to both receptor tyrosine kinases and G protein-coupled receptors (Burgering et al., 1993a; LangeCarter et al., 1993) .
Because cAMP exerts opposite effects on cell proliferation in different cell types (Pastan et al., 1975; Dumont et al., 1989) , it is reasonable to ask which elements of the MAPK pathway are targets for cAMP regulation. cAMP is known to inhibit MAPK activation in Rat-i cells (Burgering et al., 1993b; Wu et al., 1993) , smooth muscle cells (Graves et al., 1993) , CHO cells and adipocytes (Sevetson et al., 1993) , and to stimulate the MAPK pathway in COS (Faure et al., 1994) and PC12 cells (Frodin et al., 1994) . Accordingly, we investigated cAMP regulation of the MAPK cascade in three cell types: Rat-i cells, in which cAMP inhibits cell proliferation, Swiss-3T3 cells, in which cAMP stimulates cell proliferation (Rozengurt et al., 1981) , and COS-7 cells, in which we have already shown that cAMP activates MAPK (Faure et al., 1994) . Our results indicate that in certain cells cAMP inhibits Ras-dependent stimulation of Raf kinase without inhibiting downstream components of the MAPK cascade.
MATERIALS AND METHODS

DNA Constructs
The plasmids used in this work are from the following origins: pHA-MAPK1, Chinese hamster cDNA encoding an HA-tagged p44mapk (Meloche et al., 1992) , and pHA-MAPKK, Chinese hamster cDNA encoding a HA-tagged p45maPkk (Pages et al., 1994) , were gifts from J. Pouyssegur, (CNRS, Nice, France). pRaf-EE, cDNA encoding a Glu-Glu-tagged version of Raf-1 (Stokoe et al., 1994) , was a gift from D. Stokoe and J. Hancock (Onyx Pharmaceuticals, Richmond, CA) . The plasmid pGEX-MAPK1, for expression in Escherichia coli of MAPK1 as GST fusion, was constructed as follows. We made use of an EcoRI site present at the junction between the sequence encoding the HA epitope and the MAPK1 coding sequence in pHA-MAPK1. A 1.8-kb EcoRI fragment from pHA-MAPK1 was inserted in frame into pGEX-3X (Smith and Johnson, 1988) at the EcoRI site. Colonies containing plasmids with the insert in the right orientation were identified by the appearance of an -70-kDa protein fusion (26 kDa for GST plus 44 kDa for MAPK1) after quick purification on glutathione-agarose beads as described (Smith and Johnson, 1988) .
Cell Culture and DNA Transfection COS-7 and Rat-i cells were propagated in DMEM (1 g/l glucose) with 10% fetal calf serum. Swiss-3T3 cells were propagated in DMEM (1 g/l glucose) with 10% calf serum. COS-7 cells were transfected by the DEAE-dextran/chloroquine method as previously described (Conklin et al., 1992) . Cells were serum starved for 18 h in serum-free medium containing 0.1% bovine serum albumin before Raf-1, MEK, and MAPK assays.
Immunoblots
Total protein extracts were resolved by 10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose, and probed with specific antibodies. Detection was performed with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence reagents (both from Amersham, Arlington Heights, IL). The mouse monoclonal anti-MEK1 and anti-MEK2 antibodies, the rabbit polyclonal anti-MEK1 and 2 antibody, and the mouse monoclonal anti-Raf-A antibody were obtained from Transduction Laboratories (Lexington, KT) and were used at 1 ,ug/ml. The rabbit polyclonal anti-Raf-B antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA) and was used at 0.5 ,ug/ml. The rabbit polyclonal anti-ERK1 (E1.2) and anti-ERK2 (E2.1) antisera were generous gifts from S. Cook (Onyx Pharmaceuticals) and were used at a 1/1500 dilution. The rabbit polyclonal anti-Raf-1 serum was a generous gift from R. Schatzman (Syntex Research, Palo Alto, CA).
Production of bt-MAPK p44mapk used as a substrate for MEK assays was produced in E. coli (DH5a) as a GST fusion expressed from the plasmid pGEX-MAPK1. LB medium (1.8 liters) containing 50 ,zg/ml ampicillin was inoculated with 30 ml of a saturated preculture; expression was induced at OD6. = 0.5 by adding 0.2 mM isopropyl B-D-thiogalactoside (IPTG). Three hours later the cells were harvested by centrifugation (10 min, 4°C, 4000 x g) and frozen in liquid nitrogen. Cells were lysed in 30 ml of STE buffer (50 mM Tris pH 7.2, 150 mM NaCl, 1 mM EDTA) plus protease inhibitors (0.1 mM PMSF, 1.5 ,uM pepstatin, 2 ,ug/ml leupeptin, and 4 ,ug/ml aprotinin) and lysozyme (500 ,ug/ml). After a 15-mn incubation on ice, MgCl2 (2.5 mM) and DNAse 1 (50 ,Lg/ml) were added and the incubation was continued for another 30 min. Insoluble material was pelleted by centrifugation (15 min, 4C, 27,000 x g). The GST fusion protein was purified using 2 ml of glutathione-agarose beads (Sigma) as described (Smith and Johnson, 1988) . The recombinant protein was purified on a Glu-Glu monoclonal antibody affinity column as described .
Measurement of p42maPk Activity
Cells were seeded in 50-mm plates and serum starved when they reached subconfluence. Eighteen hours later the cells were stimulated with various agonists as described in the figure legends, rinsed twice with 4 ml of Ca2+-and Mg2+-free ice-cold phosphate-buffered saline, and lysed in 0.6 ml of cold lysis buffer (50 mM Tris, pH 7.5, 100 mM NaCl, 5 mM EDTA, 1 mM dithiothreitol [DTT] , 40 mM Na4P207, 200 puM Na3VO4, 1% Triton-XO00, 0.1 mM PMSF, 1.5 p.M pepstatin, 2 ,ug/ml leupeptin, and 4 jig/ml aprotinin). After a 20-min incubation on ice the cells were scraped off with a rubber policeman, and the liquid was transferred into a 1.5-ml microtube and centrifuged (5 mn, 4°C, 13,000 rpm) to pellet insoluble material. The supernatant was then transferred into a new microtube; protein concentration was determined using the Bio-Rad DC kit (Richmond, CA) to ensure that the amount of protein per sample stayed within a 10% margin. Endogenous g42mapk activity was measured essentially as described for p44H -mapk (Faure et al., 1994) except that p42maPk (ERK2) was immunoprecipitated using a rabbit polyclonal antibody ERK2 (C-14) from Santa Cruz Biotechnology (Santa Cruz, CA). Assays were performed in duplicate on 200 ,ul of cell lysate using 1 ,ug of antibody. Phosphorylation reactions were performed in 50 ,ul of kinase buffer (40 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid [HEPES], pH 7.5, 5 mM magnesium acetate, 2 mM DTT, 1 mM EGTA, and 200 ,uM Na3VO4,) supplemented with myelin basic protein (MBP; 250 ,ug/ml) and [_?2P]ATP (50 ,uM, 2 ,uCi/sample). The amount of radioactivity incorporated into MBP was determined by chromatography on P81 paper and scintillation counting as described (Faure et al., 1994) .
Measurement of MEK Activity
Endogenous MEK activity was measured by an immune-complex kinase assay performed on cell lysates prepared in the same way as for the p42maPk assay. MEK was immunoprecipitated using a rabbit polyclonal antibody directed against both MEK1 and MEK2, which was obtained from Transduction Laboratories. To confirm our results, the assay was also performed using the 12CA5 monoclonal antibody (Green et al., 1982) ,ul of kinase buffer (see above) supplemented with bacterially produced MAPK (40 ,ug/ml) and [ j)P]ATP (50 puM, 5 ,uCi/sample).
After a 20-min incubation at room temperature, the reaction was stopped by addition of 15 ,ul of 5x SDS sample buffer and incubation at 95'C for 2 min. One-half (35 ikl) of each sample was then subjected to SDS-PAGE (10% acrylamide); gels were dried and autoradiographed, and the radioactivity incorporated into bt-MAPK was quantified using a Phosphorlmager (Molecular Dynamics, Sunnyvale, CA). Two types of negative controls were performed: first, basal and EGF-stimulated samples were treated in the same way as the others but without anti-MEK antibody; second, a blank kinase reaction was performed without adding any immunoprecipitate to measure MAPK autophosphorylation. The value of the blank was subtracted from that of other samples; controls without anti-MEK antibody were not significantly different from the blank.
Measurement of Raf-1 Activity
Endogenous Raf-1 activity was measured by an immune-complex kinase assay performed on cell lysates prepared in the same way as for the p42maPk assay, except that 100-mm plates were used and cells were lysed in 0.8 ml of lysis buffer. Raf-1 protein was immunoprecipitated with a rabbit polyclonal antibody directed against Raf-1 (C-12) from Santa Cruz Biotechnology. To confirm our results, the assay was also performed using the Glu-Glu monoclonal antibody (Grussenmeyer et al., 1985) to immunoprecipitate a Glu-Glu-tagged Raf-1 protein after transient transfection of the pRaf-EE plasmid into COS-7 cells. Assays were performed in duplicate on 400 ,ul of cell lysate using 1.5 gg of antibody. Immune complexes were brought down with 30 ,ul (50% slurry) of Protein A-agarose beads (Life Technologies). Raf-1 activity was measured in 50 ,ul of Raf kinase buffer (40 mM HEPES, pH 7.5, 100 mM NaCl, 10 mM MgCl2, 2 mM DTT, and 1 mM EGTA) supplemented with kinase-inactive MEK-B protein (40 ,ug/ml) and uM, 5 , uCi/sample) . After a 30-min incubation at 37°C the reaction was stopped by addition of 15 ,ul of 5x SDS sample buffer and incubation at 95°C for 2 min. One-half (35 ,ul) of each sample was then subjected to SDS-PAGE (10% acrylamide) and subsequently treated as described for the MEK assay (see above). The same negative controls were also performed (mock I. P. and blank sample).
RESULTS
In serum-starved Rat-i, Swiss-3T3, and COS-7 cells, we studied effects of cAMP on stimulation of the MAPK pathway by EGF, which acts via a receptor tyrosine kinase, and LPA, which acts via a G proteincoupled receptor. We investigated three levels of the pathway, including MAPK itself (p42maPk), MEK (MEK1 and 2), and Raf-1. Intracellular cAMP was elevated by treating cells with forskolin before stimulating MAPK with EGF or LPA.
Effect of cAMP on p42maPk (ERK2) Activity We measured endogenous p42maPk by an immunecomplex kinase assay. Both EGF and LPA activated p42maPk in all three cell lines (Figure 1 ), although fold-stimulation was lower in COS-7 cells (EGF, 4.5-fold; LPA, 4.8-fold) than in Rat-i (EGF, 14.7-fold; LPA, 7.8-fold) and Swiss-3T3 (EGF, 12.9-fold; LPA, 7.7-fold) cells. The lower fold-response in COS-7 cells was associated with increased basal MAPK activity, perhaps because cells of this transformed line do not enter the Go phase upon serum starvation. cAMP exerted dramatically different effects on the three cell lines. In agreement with previous reports (Burgering et al., 1993b; Wu et al., 1993) , cAMP markedly inhibited basal p42rmaPk activity and abolished the response to EGF or LPA (Figure 1 ). In contrast, forskolin by itself stimulated p42maPk activity 2.5-fold and failed to block EGF and LPA stimulation in both Swiss-3T3 and COS-7 cells. In accord with the known stimulatory effect of cAMP on mitogenesis in Swiss-3T3 cells (Rozengurt et al., 1981) MEK activity was measured by an immune-complex kinase assay. To insure the validity of these results, we wanted to be sure that the polyclonal antibody we used could immunoprecipitate both MEK isoforms and that the amounts of MEK protein immunoprecipitated were not lower in LPA-treated samples. The antibody used in the MEK assays is described by the manufacturer as being able to recognize both MEKi and MEK2; this was confirmed for the cell lines we used (see Figure 4, Effect of cAMP on Raf-1 Activity Because Raf-1 kinase can directly activate MEK, and because cAMP inhibits Ras-dependent activation of Raf-1 in Rat-i cells , we assessed the regulation of Raf-1 activity by forskolin, EGF, and LPA (Figure 3) . In Rat-i cells ( Figure 3A ) both EGF and LPA stimulated Raf-i activity, although the stimulation by LPA was modest (1.5-fold). Forskolin completely blocked stimulation of Raf-1 by both EGF and LPA. Confirming previous observations Wu et al., 1993) , these results suggest that inhibition of Raf-1 activation mediates cAMP's negative regulation of the MAPK pathway in Rat-i cells.
In COS-7 cells ( Figure 3C ), both EGF and LPA strongly stimulated Raf-1 activity (37-and 17-fold, respectively) . Surprisingly, forskolin dramatically inhibited activation of Raf-1 by both EGF and LPA (95% and 91% inhibition, respectively). For unknown reasons, the Raf-1 assay produced weak signals in Swiss- cells, was blocked by forskolin ( Figure 3B ). The apparent potentiating effect of forskolin on LPA stimulated Raf-i activity in Swiss-3T3 cells ( Figure 3B ) was not seen in other experiments and is probably the result of experimental variation. cAMP inhibited Raf-1 activation by EGF in COS-7 and Swiss-3T3 cells, just as it did in Rat-i cells. This parallel inhibition of Raf-1 contrasts sharply with the opposite effects of cAMP on activation of p42maPk in COS-7 and Swiss-3T3 versus Rat-i cells (Figure 1 ). This contrast indicates that in COS-7 and Swiss-3T3 cells, a stimulatory signal initiated by EGF is transmitted to MEK and MAPK through pathways that are independent of Raf-1 and insensitive to inhibition by cAMP. In COS-7 cells, LPA also appeared to stimulate p42mapk by a cAMP-insensitive pathway that bypasses Raf-1. Finally, it is likely that the small inhibitory effect of cAMP on MEK activation observed in COS-7 cells ( Figure 2C ) resulted from the marked cAMP-induced reduction in Raf-i activity, which presumably abrogated part of the stimulatory signal received by MEK.
Endogenous Raf-i activities in Figure 3 were measured by an immune-complex assay after immunoprecipitation of Raf-i protein with a specific antibody. In COS-7 cells we obtained similar results (our unpublished results) measuring the activity of a transiently expressed, epitope-tagged Raf-1 protein.
Expression Pattern of Kinase Isoforms
To ask whether different patterns of cAMP regulation of the MAPK pathway correlate with the presence or absence of a particular kinase isoform, we used antibodies directed against specific kinase isoforms to determine the expression of individual kinases in ex-
tracts of Rat-i, Swiss-3T3, and COS-7 cells (Figure 4 ). No such correlation was apparent. More specifically: of the three known Raf kinase isoforms (Huleihel et al., 1986; Sithanandam et al., 1990; Stephens et al., 1992) , Raf-1 (74 kDa) and Raf-A (68 kDa) were expressed at comparable levels in all three cell lines; of the two Raf-B isoforms, COS-7 cells expressed small amounts of the 95-kDa protein and none of the 68-kDa protein, whereas Rat-i cells expressed the 68-kDa isoform and trace amounts of the 95-kDa isoform. Swiss-3T3 cells expressed large quantities of both isoforms, especially the one that migrates at 68-kDa. MEK1 and MEK2 are the two main isoforms of MEK (Crews et al., 1992; Zheng and Guan, 1993a) . A third isoform MEK3 is similar to MEK1 except for a 26-residue deletion caused by alternative splicing (Zheng and Guan, 1993b) ; because the epitopes used to raise the anti-MEK1 antibody we used are shared with MEK3, MEK3 would probably be recognized by that antibody. Figure 4 shows that all three cell lines contained both MEK1 and MEK2. The antibody used for the immune complex kinase assays is directed against both MEK1 and MEK2; indeed this antibody detected doublet bands in extracts of Swiss-3T3 and Rat-i cells the same pattern of activation. The only known exception is that p42maPk, but not p44maPk, becomes activated in thrombin-induced platelet activation (Papkoff et al., 1994) . Here we have shown that for Rat-1 cells, which contain both p42maPk and p44maPk, the regulation pattern was identical for both isoforms (see above). In summary, because all three cell lines express both MEK1 and MEK2, the weak stimulation of MEK by LPA in Rat-1 and Swiss-3T3 cells, relative to COS-7 cells, cannot be accounted for by differences in MEK isoforms. Similarly, Raf-B showed distinct patterns of expression in the three cell lines, but these did not agree with different responses of the cell lines to cAMP. In particular, expression of Raf-B did not correlate with the presence of a Raf-1-independent and cAMP-insensitive pathway.
DISCUSSION
We have assessed the effects of cAMP on responses of the MAPK pathway to EGF and LPA in three cell lines. In Rat-1 cells, cAMP inhibits mitogenesis, whereas in Swiss-3T3 cells it has a modest mitogenic effect on its own and synergizes with other mitogens (Rozengurt et al., 1981) . As expected, we found that cAMP effects on EGF-stimulated MAP kinase activities paralleled its effects on mitogenesis in both these cell lines. The inhibitory effects of cAMP we observed in Rat-1 cells confirm previous reports (Burgering et al., 1993; Wu et al., 1993b) Figure 5) . A similar situation has been described in PC12 cells (Vaillancourt et al., 1994) , where cAMP inhibits both 
Swiss-3T3 Cells
In keeping with the known effects of cAMP on mitogenesis in these cells, forskolin stimulated the MAP kinase pathway on its own and slightly increased the MAPK response to both EGF and LPA (see Figure 1) . In contrast to its effect on MAPK activity, forskolin alone did not increase MEK activity in these cells; the mechanism by which cAMP stimulates MAPK activity is unknown. Although the activity of Raf-1 kinase appeared to be generally reduced in Swiss-3T3 cells, forskolin clearly blocked EGF stimulation of Raf-1 despite its inability to block EGF stimulation of MAP kinase. It is possible that the modest EGF-induced increase in Raf-1 activity observed in Swiss-3T3 cells indicates that a kinase distinct from Raf-1 plays a more important role in mediating the mitogenic response to EGF in these cells.
COS-7 Cells
As in Swiss-3T3 cells, forskolin did not inhibit EGF-or LPA-induced elevations of MAPK activity in COS-7 cells. Forskolin strongly inhibited elevations of Raf-1 activity in response to either EGF or LPA in COS-7 cells. The ability of cAMP to inhibit Raf-1 stimulation in all three cell lines is not necessarily surprising, because all three cell lines express the same Raf-1 gene and cAMP probably exerts its inhibitory effect by causing phosphorylation of Raf-1 by cAMP-dependent protein kinase Wu et al., 1993) . The failure of increased cellular cAMP to block growth factor-induced increases in MEK and MAP kinase activities indicates that growth factors in COS-7 cells, like Swiss-3T3, can trigger a pathway that is both independent of Raf-1 and insensitive to cAMP.
Other Possible Pathways Although our results point to the existence of a Rafindependent, cAMP-insensitive avenue for MAP kinase activation in Swiss-3T3 or COS-7 cells, they do not indicate the mechanism by which mitogenic stimuli in these cells manage to bypass Raf-1. Part of the signal generated by the EGF receptor in COS cells can bypass Ras, as shown by the ability of EGF to stimulate a recombinant Raf-1 that is engineered to bind constitutively to the plasma membrane, even in the presence of a dominant-negative mutant Ras (Leevers et al., 1994; Stokoe et al., 1994) . The mechanism of this Ras-independent signal is not known, and its sensitivity to inhibition by cAMP has not been tested. It may or may not be relevant to the Raf-independent, cAMPinsensitive mechanism(s) utilized by EGF to stimulate the MAP kinase pathway in COS-7 and Swiss-3T3 cells.
Our proposal of a Raf-l-independent pathway assumes that Raf-1 activates MEK and that the extent of MEK activation directly and proportionally reflects the extent of Raf-1 activation. Our data, however, do not rule out the possibility that a low level of Raf-1 activity can fully activate MEK in Swiss-3T3 and COS-7 cells but not in Rat-i cells, owing to, for example, a MEK-directed phosphatase with much greater activity in Rat-i cells than in Swiss-3T3 or COS-7 cells.
Indeed, the postulated Raf-independent, cAMP-insensitive pathway could itself regulate the mechanism responsible for lack of proportion between Raf-i and MEK activities (e.g., by decreasing MEK dephosphorylation in Swiss-3T3 and COS-7 cells).
Expression patterns of Raf isoforms did not correlate with responses of mitogenic pathways to cAMP (see Figure 4) , i.e., the presence of Raf-l-independent and cAMP-insensitive pathway(s) did not correlate with Raf-A and Raf-B expression. MEKK (Lange-Carter et al., 1993) is an additional potential activator of MEK, and others will certainly be found in future studies. We suspect that MEKK is not the basis of a Raf-lindependent pathway, for two reasons: 1) although EGF and NGF lead to MEKK activation in PC12 cells, this effect is blocked by cAMP (Lange-Carter and Johnson, 1994); 2) In COS-7 cells, EGF does not activate an HA-tagged MEKK construct (VoynoYasenetskaya and Bourne, unpublished observation). Each of the many pathways leading to activation of MAPK will probably prove to contain specific elements and elements shared with other pathways. MAP kinase stimulation is likely to depend on Raf-1 in many of the cells in which cAMP inhibits mitogenesis. In cells where cAMP is mitogenic-including many endocrine target cells-one or more mechanisms will be discovered that allow stimulation of MAP kinase to bypass Raf-1.
